A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease (SPRING)
30. listopadu 2016 aktualizováno: MedImmune LLC
A Phase 2 Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the effect of MEDI8968 on the rate of moderate or severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in adult subjects with symptomatic, moderate to very severe COPD (Global Initiative for Chronic Obstructive Lung Disease - GOLD stage II-IV) receiving standard maintenance therapy for the underlying disease condition.
Přehled studie
Postavení
Dokončeno
Podmínky
Intervence / Léčba
Detailní popis
A Phase 2 double-blind, placebo-controlled study to evaluate the efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease.
The study will have a screening phase of 23 days, treatment phase from Week 1 to 53 and follow-up phase from Week 53 to 69.
Participants will receive either MEDI8968 600 milligram (mg) as intravenous (IV) infusion on Day 1 followed by 300 mg injection subcutaneously (SC) every 4 weeks up to Week 53 or matching placebo in the same fashion.
Participants will primarily be assessed for incidence rate of moderate or severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
Safety will be monitored throughout the study.
Typ studie
Intervenční
Zápis (Aktuální)
464
Fáze
- Fáze 2
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
-
Plovdiv, Bulharsko
- Research Site
-
Ruse, Bulharsko
- Research Site
-
Sofia, Bulharsko
- Research Site
-
Stara Zagora, Bulharsko
- Research Site
-
Veliko Tarnovo, Bulharsko
- Research Site
-
-
-
-
-
Iloilo City, Filipíny
- Research Site
-
Lipa City, Filipíny
- Research Site
-
Quezon City, Filipíny
- Research Site
-
-
-
-
-
Kaunas, Litva
- Research Site
-
Klaipeda, Litva
- Research Site
-
Vilnius, Litva
- Research Site
-
-
-
-
-
Daugavpils, Lotyšsko
- Research Site
-
Riga, Lotyšsko
- Research Site
-
-
-
-
-
Balassagyarmat, Maďarsko
- Research Site
-
Budapest, Maďarsko
- Research Site
-
Farkasgyepü, Maďarsko
- Research Site
-
Komarom, Maďarsko
- Research Site
-
Mateszalka, Maďarsko
- Research Site
-
Matrahaza, Maďarsko
- Research Site
-
Mosonmagyarovar, Maďarsko
- Research Site
-
Nagykanizsa, Maďarsko
- Research Site
-
Szikszo, Maďarsko
- Research Site
-
Tatabanya, Maďarsko
- Research Site
-
Torokbalint, Maďarsko
- Research Site
-
-
-
-
-
Bialystok, Polsko
- Research Site
-
Gdansk, Polsko
- Research Site
-
Krakow, Polsko
- Research Site
-
Lodz, Polsko
- Research Site
-
Oswiecim, Polsko
- Research Site
-
Poznan, Polsko
- Research Site
-
Wroclaw, Polsko
- Research Site
-
Zgierz, Polsko
- Research Site
-
-
-
-
-
Cambridge, Spojené království
- Research Site
-
Newcastle upon Tyne, Spojené království
- Research Site
-
Wolverhampton, Spojené království
- Research Site
-
-
-
-
Arizona
-
Peoria, Arizona, Spojené státy
- Research Site
-
-
Florida
-
Clearwater, Florida, Spojené státy
- Research Site
-
-
Georgia
-
Duluth, Georgia, Spojené státy
- Research Site
-
-
Maine
-
Auburn, Maine, Spojené státy
- Research Site
-
-
New York
-
Buffalo, New York, Spojené státy
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Spojené státy
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy
- Research Site
-
-
South Carolina
-
Greenville, South Carolina, Spojené státy
- Research Site
-
Spartanburg, South Carolina, Spojené státy
- Research Site
-
-
Texas
-
Boerne, Texas, Spojené státy
- Research Site
-
-
Virginia
-
Richmond, Virginia, Spojené státy
- Research Site
-
-
-
-
-
Ivano-Frankivsk, Ukrajina
- Research Site
-
Kharkiv, Ukrajina
- Research Site
-
Kyiv, Ukrajina
- Research Site
-
Odessa, Ukrajina
- Research Site
-
Poltava, Ukrajina
- Research Site
-
Simferopol, Ukrajina
- Research Site
-
Vinnytsya, Ukrajina
- Research Site
-
-
-
-
-
Brno, Česká republika
- Research Site
-
Jindrichuv Hradec, Česká republika
- Research Site
-
Karlovy Vary, Česká republika
- Research Site
-
Plzen, Česká republika
- Research Site
-
Praha 10, Česká republika
- Research Site
-
Strakonice, Česká republika
- Research Site
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
45 let až 75 let (Dospělý, Starší dospělý)
Přijímá zdravé dobrovolníky
Ne
Pohlaví způsobilá ke studiu
Všechno
Popis
Inclusion Criteria:
- Age 45 through 75 years
- Predicted (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage II, III, and IV) at Screening
- History of previous acute exacerbations of chronic obstructive pulmonary disease (AECOPD) 12 months prior to Screening
- Clinically stable and free from an AECOPD for 8 weeks prior to Day 1
- Current smoker or ex-smoker with a tobacco history of more than or equal to (>=) 10 pack-years.
Exclusion Criteria:
- Past or present disease or disorder,
- Significant or unstable ischemic heart disease etc
- Known history of allergy or reaction to any component of the investigational manufacturing product (IMP)
- Past or current malignancy within the past 5 years
- Subjects have had a chest x-ray or Computed Tomography (CT) scan suggestive of malignancy or tuberculosis (TB).
- Use of immunosuppressive medication receipt of any biologic agent.
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Komparátor placeba: Placebo
Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
|
Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
|
|
Experimentální: MEDI8968 600 mg IV, 300 mg SC
MEDI8968 600 milligram (mg) as intravenous (IV) infusion on Day 1 followed by 300 mg injection subcutaneously (SC) every 4 weeks up to Week 53.
|
MEDI8968 600 mg as IV infusion on Day 1 followed by 300 mg injection SC every 4 weeks up to Week 53.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Mean Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)
Časové okno: Day 1 up to 393
|
An AECOPD is defined as worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days.
The severity of an AECOPD is defined as: Moderate exacerbations require treatment with systemic corticosteroids, and or antibiotics.
Severe exacerbations require hospitalization.
The AECOPD rate was analyzed using a Poisson Regression model adjusted for over dispersion with number of exacerbations as the outcome and the log of follow-up time as an offset variable, with covariates for treatment group (MEDI8986, placebo), background maintenance therapy and previous exacerbations.
Mean exacerbations were presented as number of exacerbations/year.
|
Day 1 up to 393
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Mean Rate of Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)
Časové okno: Day 1 up to 393
|
An AECOPD is defined as worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days.
Severe exacerbations require hospitalization.
The AECOPD rate was analyzed using a Poisson Regression model adjusted for over dispersion with number of exacerbations as the outcome and the log of follow-up time as an offset variable, with covariates for treatment group (MEDI8986, placebo), background maintenance therapy and previous exacerbations.
Mean exacerbations were presented as number of exacerbations/year.
|
Day 1 up to 393
|
|
Time to First Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)
Časové okno: Day 1 up to 393
|
Time to first worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days.
The severity of an AECOPD is defined as: Mild exacerbations require treatment with an increase in usual therapy, e.g., increase use of short acting bronchodilators.
Moderate exacerbations require treatment with systemic corticosteroids, and or antibiotics.
Severe exacerbations require hospitalization.
|
Day 1 up to 393
|
|
Change From Baseline in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total and Subscales Scores at Week 53
Časové okno: Baseline and Week 53
|
The SGRQ is a health related quality of life questionnaire consisting of 40 items in three domains: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease).
Each question's response has a unique empirically derived weight where lowest possible weight is zero and the highest is 100.
The total score and domain score are derived from the relevant items and converted to a score of 0 to 100 with a higher score indicating poorer health status.
|
Baseline and Week 53
|
|
Percentage of Participants With Improvement in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total Score
Časové okno: Week 53
|
The SGRQ is a health related quality of life questionnaire consisting of 40 items in three domains: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease).
Each question's response has a unique empirically derived weight where lowest possible weight is zero and the highest is 100.
The total score and domain score are derived from the relevant items and converted to a score of 0 to 100 with a higher score indicating poorer health status.
A 4-point change in total score demonstrates a clinically meaningful change, while an 8-point change and a 12-point change are interpreted as a moderate and large change in health status, respectively.
|
Week 53
|
|
Change From Baseline in Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Score at Week 53
Časové okno: Baseline and Week 53
|
The BODE index is a multi-dimension COPD grading system that incorporates body-mass index (B), degree of airflow obstruction (O), dyspnea (D), and exercise capacity (E) as measured by the modified medical research council (MMRC) dyspnea scale and the 6-minute walk test.
The MMRC dyspnea scale is a 5-point scale that measures the level of dyspnea (trouble breathing) experienced by participants where score range is 0 (none) to 4 (very severe).
BODE score is derived into a score range of 0 (healthy) to 10 (severe COPD).
|
Baseline and Week 53
|
|
Percentage of Participants With Improvement in Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Score
Časové okno: Baseline and Week 53
|
The BODE index is a multi-dimension COPD grading system that incorporates body-mass index (B), degree of airflow obstruction (O), dyspnea (D), and exercise capacity (E) as measured by the modified medical research council (MMRC) dyspnea scale and the 6-minute walk test.
The MMRC dyspnea scale is a 5-point scale that measures the level of dyspnea (trouble breathing) experienced by participants where score range is 0 (none) to 4 (very severe).
BODE score is derived into a score range of 0 (healthy) to 10 (severe COPD).
Negative change score signifies improvement compared to baseline.
Number of participants with improvement in BODE score compared to baseline were reported.
|
Baseline and Week 53
|
|
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
Časové okno: Day 1 up to Week 69
|
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent are events between administration of study drug and up to Week 69 that were absent before treatment or that worsened relative to pre-treatment state.
TEAEs reported below included both SAEs and non-serious AEs.
|
Day 1 up to Week 69
|
|
Observed Serum Concentrations of MEDI8968
Časové okno: Pre-dose (Baseline), Post-dose on Week 53
|
Pre-dose (Baseline), Post-dose on Week 53
|
|
|
Number of Participants Exhibiting Anti-Drug Antibodies for MEDI8968 at Any Visit
Časové okno: Day 1 up to Week 69
|
Anti-drug antibodies for MEDI8968 were analyzed for participants who received placebo or MEDI8968 as per planned analysis.
|
Day 1 up to Week 69
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Vyšetřovatelé
- Ředitel studie: Rene Van Der Merwe, MBChB, MFPM, MedImmune Ltd
Publikace a užitečné odkazy
Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia
1. listopadu 2011
Primární dokončení (Aktuální)
1. února 2014
Dokončení studie (Aktuální)
1. února 2014
Termíny zápisu do studia
První předloženo
6. října 2011
První předloženo, které splnilo kritéria kontroly kvality
6. října 2011
První zveřejněno (Odhad)
7. října 2011
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
30. ledna 2017
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
30. listopadu 2016
Naposledy ověřeno
1. listopadu 2016
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- CD-RI-MEDI8968-1103
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .